SGLT2 inhibitors, cardiovascular outcomes, and mortality across the spectrum of kidney disease: A systematic review and meta-analysis
Spiazzi BF, Piccoli GF, Wayerbacher LF, et al.
Diabetes Res Clin Pract. 2024:111933.
Leggi
Breaking news
Time to development of macrovascular complications and its predictors among type 2 diabetes mellitus patients at Jimma University Medical Center
Adare AF, Tiyare FT, Marine BT
BMC Endocr Disord. 2024;24(1):252.
Leggi
Hypoglycemic events may trigger acute ischemic stroke within 30 days in those with diabetes: a case-crossover study
Makam S, Stein LK, Dhamoon MS
Stroke. Pub. online 22 Nov 2024.
Leggi
EMA: Updated advice to minimise risks of interaction between weight loss medicine Mysimba and opioids
15/11/2024
Leggi
AIFA: Classificazione del medicinale per uso umano, a base di Semaglutide «Rybelsus», nuove confezioni 1,5 mg – 4 mg – 9 mg in apposita sezione denominata classe C (Determina n. 655/2024)
11/11/2024
Leggi
Ministero della Salute: LINEE DI INDIRIZZO SULL’ATTIVITÀ FISICA. Revisione delle raccomandazioni per le persone con diabete mellito e per le persone sottoposte a trapianto e nuove raccomandazioni per le persone con patologie muscolo-scheletriche
11/11/2024
Leggi
Intensive blood-pressure control in patients with type 2 diabetes
Bi Y, Li M, Liu Y, et al.
N Engl J Med. Pub. online 16 Nov 2024.
Leggi
Effects of tirzepatide on the clinical trajectory of patients with heart failure, a preserved ejection fraction, and obesity
Zile MR, Borlaug BA, Kramer CM, et al.
Circulation. Pub. online 18 Nov 2024.
Leggi
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease
Ostrominski JW, Højbjerg Lassen MC, Claggett BL, et al.
Eur Heart J. 2024:ehae780.
Leggi
Results from a randomized trial of intensive glucose management using CGM versus usual care in hospitalized adults with type 2 diabetes: the TIGHT study
Hirsch IB, Draznin B, Buse JB, et al.
Diabetes Care. 2024:dc241779.
Leggi